Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Flux Power Holdings Inc (FLUX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Flux Power Holdings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Flux Power Holdings Inc trades at $0.73 (market cap $16.02M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 280.3× Flux Power Holdings Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | FLUX | |
|---|---|---|
Market Cap | $4.49B | $16.02M |
Sector | Health | Utilities |
52-Week High | $28.06 | $6.66 |
52-Week Low | $20.06 | $0.75 |
Enterprise Value | $3.69B | $22.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
FLUX trades at $0.8199, down 8.75% over 24 hours. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $6.67 million in 2025 with a negative net margin of 12.48%, while revenue declined to $51 million in 2026. Recent developments include the launch of SkyEMS 3.0 AI software and new executive appointments aimed at growth.
Outlook remains speculative with unanimous analyst buy ratings contrasting weak profitability. Key opportunities lie in software innovation and market expansion, but risks include persistent losses, revenue volatility, and intense clean energy competition. The stock's appeal hinges on execution turning losses to profits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →
